PharVision Advisers’s Krispy Kreme DNUT Stock Holding History

PharVision Advisers’s Portfolio DNUT Stock Details DNUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,096	Closed	-$62.3K	–	760
2025 Q3	$62.3K	Buy	+16,096	New	+$55.5K	0.04%	644

Other funds holding DNUT

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Banco Santander Madrid, Spain $12.4B AUM 29.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

PharVision Advisers's DNUT Position: Q4 2025 in Review

PharVision Advisers sold out of Krispy Kreme (DNUT) in Q4 2025, closing a stake of 16,096 shares — an estimated $62.3K sold.

PharVision Advisers first reported a position in DNUT in Q3 2025 and held it in 1 quarter. The position peaked at $62.3K in Q3 2025. 168 funds tracked by Wall St. Rank hold DNUT as of Q4 2025.

PharVision Advisers reported no remaining Krispy Kreme position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 16,096 Krispy Kreme shares in Q4 2025, an estimated $62.3K.
PharVision Advisers first reported a position in Krispy Kreme in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Krispy Kreme position peaked at $62.3K in Q3 2025.
168 funds tracked by Wall St. Rank held Krispy Kreme as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.